Breaking News, Collaborations & Alliances

Nona Biosciences Enters Collaboration Agreement with Dragonfly Therapeutics

Aims to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.

Author Image

By: Charlie Sternberg

Associate Editor

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from “Idea to IND”, has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona’s proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.   Through the collaboration, Nona Biosciences will provi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters